ACHE and Alzheimer disease: The inhibitory effects of these formulations on acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidase (MAO) highlight their potential in modulating cholinergic transmission and reducing oxidative stress, which are central to AD pathogenesis.